source
- UnitedHealth beats Q2 forecasts but warns rising insurance costs will strain employersUnitedHealth Group reported second-quarter results that exceeded analysts' expectations, lifting its shares modestly. Despite the upbeat earnings, executives highlighted that medical expenses for…
- Takeda's zasocitinib clears scalp psoriasis in 75% of patients in phase 3 dataTakeda released updated results from its two phase 3 trials of the oral TYK2 inhibitor zasocitinib, enrolling a total of 1,801 patients with moderate-to-severe plaque psoriasis. The data showed th…